FDA Approves Emrosi for Rosacea in Adults

Medically reviewed by Drugs.com.

By Lori Solomon HealthDay Reporter

TUESDAY, Nov. 12, 2024 -- The U.S. Food and Drug Administration has approved Emrosi (minocycline hydrochloride) for the treatment of inflammatory rosacea in adults.

The extended-release capsules (40 mg) will be available late in the first quarter or early in the second quarter of 2025.

The approval was based on positive results from two 16-week phase 3 clinical trials, during which Emrosi met all coprimary and secondary end points and showed significant superiority over both the current standard-of-care treatment (Oracea) and placebo for Investigator’s Global Assessment treatment success as well as reduction in total inflammatory lesion count. Additionally, participants experienced no significant safety issues.

"Rosacea is a difficult to treat skin condition, and based on the favorable results from our phase 3 clinical trials, Emrosi has potential to become the best-in-class oral medication to treat the condition," Claude Maraoui, the cofounder, president, and CEO of Journey Medical, said in a statement. "Our seasoned dermatology-focused sales force is now preparing for a successful launch and to establish Emrosi as a new standard of care in the treatment of rosacea."

The approval of Emrosi was granted to Journey Medical.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords